DREAMM-2: Exploration of BCVA, Ocular Symptoms, and OSDI Questionnaire as Surrogates for Corneal Alterations During Treatment With Belantamab Mafodotin in R/R MM

June 4-8, 2021; Online at https://conferences.asco.org/am
Post-hoc analysis of the DREAMM-2 findings suggest that BCVA changes and patient-reported ocular symptoms are concordant with corneal exam findings after belantamab mafodotin treatment in the majority of cases.
Format: Microsoft PowerPoint (.ppt)
File Size: 457 KB
Released: June 5, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Related Content

Downloadable slideset from S. Vincent Rajkumar, MD and Thomas G. Martin, MD, on considerations for treatment of multiple myeloma at first relapse, provided by Clinical Care Options (CCO)

Thomas G. Martin, MD S. Vincent Rajkumar, MD Released: December 29, 2022

Webcast from a live meeting series presented by Dr Sarah Holstein on advancements in first-line care for newly diagnosed multiple myeloma, from Clinical Care Options (CCO)

Sarah A. Holstein, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Phase I/II trial of mezigdomide + dexamethasone in relapsed/refractory multiple myeloma, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 19, 2022

Long-term PFS data exploring duration of lenalidomide maintenance therapy in patients with multiple myeloma after ASCT, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings